SCHEMBL21392794

SCHEMBL21392794

C=CC(=O)N(c1ccccc1)C(C)(C)CC

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 4/20 0.40
TSHR P16473 2/20 0.40
GLA P06280 1/20 0.40
TP53 P04637 1/20 0.39
RIPK1 Q13546 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
AKT1 P31749 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
GSTO1 P78417 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7891310 0.83 CYP2C19 (0.41) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL21392847 0.82 BCL2A1 (0.49) KMT2AMEN1SMN1; SMN2ALDH1A1TSHR
SCHEMBL25542682 0.78 KMT2A (0.43) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL7142800 0.76 AKT1 (0.39) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL21392780 0.75 ALDH1A1 (0.53) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL27490821 0.75 ALDH1A1 (0.40) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL194846 0.73 ALDH1A1 (0.63) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL23861653 0.72
SCHEMBL3280077 0.70 ALDH1A1 (0.46) KMT2AMEN1ALDH1A1TSHRGLA
SCHEMBL319608 0.70 KMT2A (0.46) KMT2AMEN1SMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 US disclosed
WO-2019183600-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-09-26 WO disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 KMT2A 3168/4885MEN1 4319/4885CYP3A4 3787/4885
US-11666661-B2 Methods and compounds for targeted autophagy ATG7, BECN1, SQSTM1 KMT2A 3168/4885MEN1 4319/4885CYP3A4 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.